SABCS 2016

Duloxetine treatment is superior to placebo for managing aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS).

Subpopulations of tumor cells can form microanatomic associations with endothelial cells and macrophages.

Neoadjuvant therapy with the investigational oral CDK 4/6 inhibitor abemaciclib as monotherapy and with anastrozole reduced Ki67 levels.

Adding the PI3K inhibitor buparlisib to fulvestrant endocrine therapy improves progression-free survival (PFS).

Circulating tumor microRNA signatures might discriminate between neoadjuvant chemotherapy-responsive and -unresponsive HER2+ breast cancers.

Post-mastectomy radiotherapy is associated with increased rates of complications like hematoma, infection, and reduced patient-reported satisfaction.

Circulating tumor cell (CTC) counts prior to neoadjuvant chemotherapy for early-stage breast cancer predict survival.

Pathologic complete response (pCR) rates in hormone receptor (HR)-positive, HER2-positive breast cancer were unchanged.

BRCA1/2 mutation status does not predict survival among young patients.

Plasma tumor DNA (ptDNA) is superior to serum for analyzing the DNA shed by tumors into the bloodstream.